Drug Trial Radar · NCT02785172
Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Aug 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
154
Actual
Start
Apr 2016
Primary completion
Dec 2016
Study completion Jan 2017
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 27, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Safety and Efficacy of IDP-118 Lotion to Ultravate® Cream, in the Treatment of Plaque Psoriasis
Conditions
- Psoriasis
Interventions
IDP-118 Vehicle LotionDrug
Vehicle
IDP-118 Vehicle CreamDrug
Vehicle
IDP-118 LotionDrug
Lotion
Ultravate CreamDrug
Cream
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of Subjects With Treatment SuccessTime frame: 2 weeks
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Valeant Site 12
Fullerton, California
Valeant Site 04
La Mesa, California
Valeant Site 03
San Diego, California
Valeant Site 09
San Diego, California
Valeant Site 05
Lauderdale Lakes, Florida
Valeant Site 02
Miami, Florida
Valeant Site 07
Fridley, Minnesota
Valeant Site 08
Chapel Hill, North Carolina
Valeant Site 06
Columbus, Ohio
Valeant Site 13
Mt. Pleasant, South Carolina
Valeant Site 11
Katy, Texas
Valeant Site 10
San Antonio, Texas
Valeant Site 01
Sugar Land, Texas
Valeant Site 14
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.